Health-related quality of life results from the phase III CheckMate 067 study.
Identifieur interne : 000640 ( PubMed/Corpus ); précédent : 000639; suivant : 000641Health-related quality of life results from the phase III CheckMate 067 study.
Auteurs : Dirk Schadendorf ; James Larkin ; Jedd Wolchok ; F Stephen Hodi ; Vanna Chiarion-Sileni ; Rene Gonzalez ; Piotr Rutkowski ; Jean-Jacques Grob ; C Lance Cowey ; Christopher Lao ; John Wagstaff ; Margaret K. Callahan ; Michael A. Postow ; Michael Smylie ; Pier Francesco Ferrucci ; Reinhard Dummer ; Andrew Hill ; Fiona Taylor ; Javier Sabater ; Dana Walker ; Srividya Kotapati ; Amy Abernethy ; Georgina V. LongSource :
- European journal of cancer (Oxford, England : 1990) [ 1879-0852 ] ; 2017.
English descriptors
- KwdEn :
- Adult, Aged, Antibodies, Monoclonal (administration & dosage), Antibodies, Monoclonal (therapeutic use), Antineoplastic Agents (therapeutic use), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Double-Blind Method, Female, Health Status, Humans, Male, Melanoma (drug therapy), Middle Aged, Quality of Life.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal.
- chemical , therapeutic use : Antibodies, Monoclonal, Antineoplastic Agents.
- drug therapy : Melanoma.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Double-Blind Method, Female, Health Status, Humans, Male, Middle Aged, Quality of Life.
Abstract
Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067.
DOI: 10.1016/j.ejca.2017.05.031
PubMed: 28651159
Links to Exploration step
pubmed:28651159Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Health-related quality of life results from the phase III CheckMate 067 study.</title><author><name sortKey="Schadendorf, Dirk" sort="Schadendorf, Dirk" uniqKey="Schadendorf D" first="Dirk" last="Schadendorf">Dirk Schadendorf</name><affiliation><nlm:affiliation>Department of Dermatology, University of Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Larkin, James" sort="Larkin, James" uniqKey="Larkin J" first="James" last="Larkin">James Larkin</name><affiliation><nlm:affiliation>Royal Marsden Hospital, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Wolchok, Jedd" sort="Wolchok, Jedd" uniqKey="Wolchok J" first="Jedd" last="Wolchok">Jedd Wolchok</name><affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hodi, F Stephen" sort="Hodi, F Stephen" uniqKey="Hodi F" first="F Stephen" last="Hodi">F Stephen Hodi</name><affiliation><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Chiarion Sileni, Vanna" sort="Chiarion Sileni, Vanna" uniqKey="Chiarion Sileni V" first="Vanna" last="Chiarion-Sileni">Vanna Chiarion-Sileni</name><affiliation><nlm:affiliation>Istituto Oncologico Veneto, Veneto, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Gonzalez, Rene" sort="Gonzalez, Rene" uniqKey="Gonzalez R" first="Rene" last="Gonzalez">Rene Gonzalez</name><affiliation><nlm:affiliation>University of Colorado, Denver, CO, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Rutkowski, Piotr" sort="Rutkowski, Piotr" uniqKey="Rutkowski P" first="Piotr" last="Rutkowski">Piotr Rutkowski</name><affiliation><nlm:affiliation>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.</nlm:affiliation></affiliation></author><author><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name><affiliation><nlm:affiliation>Hospital de la Timone, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Cowey, C Lance" sort="Cowey, C Lance" uniqKey="Cowey C" first="C Lance" last="Cowey">C Lance Cowey</name><affiliation><nlm:affiliation>Texas Oncology-Baylor Cancer Center, Dallas, TX, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Lao, Christopher" sort="Lao, Christopher" uniqKey="Lao C" first="Christopher" last="Lao">Christopher Lao</name><affiliation><nlm:affiliation>University of Michigan, Ann Arbor, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Wagstaff, John" sort="Wagstaff, John" uniqKey="Wagstaff J" first="John" last="Wagstaff">John Wagstaff</name><affiliation><nlm:affiliation>The College of Medicine, Swansea University, Swansea, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Callahan, Margaret K" sort="Callahan, Margaret K" uniqKey="Callahan M" first="Margaret K" last="Callahan">Margaret K. Callahan</name><affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Postow, Michael A" sort="Postow, Michael A" uniqKey="Postow M" first="Michael A" last="Postow">Michael A. Postow</name><affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Smylie, Michael" sort="Smylie, Michael" uniqKey="Smylie M" first="Michael" last="Smylie">Michael Smylie</name><affiliation><nlm:affiliation>Cross Cancer Institute, Edmonton, Alberta, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Ferrucci, Pier Francesco" sort="Ferrucci, Pier Francesco" uniqKey="Ferrucci P" first="Pier Francesco" last="Ferrucci">Pier Francesco Ferrucci</name><affiliation><nlm:affiliation>Istituto Europeo di Oncologia, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Dummer, Reinhard" sort="Dummer, Reinhard" uniqKey="Dummer R" first="Reinhard" last="Dummer">Reinhard Dummer</name><affiliation><nlm:affiliation>University of Zurich, Zurich, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Hill, Andrew" sort="Hill, Andrew" uniqKey="Hill A" first="Andrew" last="Hill">Andrew Hill</name><affiliation><nlm:affiliation>Tasman Oncology Research, Brisbane, QLD, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Taylor, Fiona" sort="Taylor, Fiona" uniqKey="Taylor F" first="Fiona" last="Taylor">Fiona Taylor</name><affiliation><nlm:affiliation>Adelphi Values, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Sabater, Javier" sort="Sabater, Javier" uniqKey="Sabater J" first="Javier" last="Sabater">Javier Sabater</name><affiliation><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Walker, Dana" sort="Walker, Dana" uniqKey="Walker D" first="Dana" last="Walker">Dana Walker</name><affiliation><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kotapati, Srividya" sort="Kotapati, Srividya" uniqKey="Kotapati S" first="Srividya" last="Kotapati">Srividya Kotapati</name><affiliation><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Abernethy, Amy" sort="Abernethy, Amy" uniqKey="Abernethy A" first="Amy" last="Abernethy">Amy Abernethy</name><affiliation><nlm:affiliation>Duke University Medical Center, Durham, NC, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Long, Georgina V" sort="Long, Georgina V" uniqKey="Long G" first="Georgina V" last="Long">Georgina V. Long</name><affiliation><nlm:affiliation>Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia. Electronic address: georgina.long@sydney.edu.au.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28651159</idno><idno type="pmid">28651159</idno><idno type="doi">10.1016/j.ejca.2017.05.031</idno><idno type="wicri:Area/PubMed/Corpus">000640</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000640</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Health-related quality of life results from the phase III CheckMate 067 study.</title><author><name sortKey="Schadendorf, Dirk" sort="Schadendorf, Dirk" uniqKey="Schadendorf D" first="Dirk" last="Schadendorf">Dirk Schadendorf</name><affiliation><nlm:affiliation>Department of Dermatology, University of Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Larkin, James" sort="Larkin, James" uniqKey="Larkin J" first="James" last="Larkin">James Larkin</name><affiliation><nlm:affiliation>Royal Marsden Hospital, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Wolchok, Jedd" sort="Wolchok, Jedd" uniqKey="Wolchok J" first="Jedd" last="Wolchok">Jedd Wolchok</name><affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hodi, F Stephen" sort="Hodi, F Stephen" uniqKey="Hodi F" first="F Stephen" last="Hodi">F Stephen Hodi</name><affiliation><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Chiarion Sileni, Vanna" sort="Chiarion Sileni, Vanna" uniqKey="Chiarion Sileni V" first="Vanna" last="Chiarion-Sileni">Vanna Chiarion-Sileni</name><affiliation><nlm:affiliation>Istituto Oncologico Veneto, Veneto, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Gonzalez, Rene" sort="Gonzalez, Rene" uniqKey="Gonzalez R" first="Rene" last="Gonzalez">Rene Gonzalez</name><affiliation><nlm:affiliation>University of Colorado, Denver, CO, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Rutkowski, Piotr" sort="Rutkowski, Piotr" uniqKey="Rutkowski P" first="Piotr" last="Rutkowski">Piotr Rutkowski</name><affiliation><nlm:affiliation>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.</nlm:affiliation></affiliation></author><author><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name><affiliation><nlm:affiliation>Hospital de la Timone, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Cowey, C Lance" sort="Cowey, C Lance" uniqKey="Cowey C" first="C Lance" last="Cowey">C Lance Cowey</name><affiliation><nlm:affiliation>Texas Oncology-Baylor Cancer Center, Dallas, TX, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Lao, Christopher" sort="Lao, Christopher" uniqKey="Lao C" first="Christopher" last="Lao">Christopher Lao</name><affiliation><nlm:affiliation>University of Michigan, Ann Arbor, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Wagstaff, John" sort="Wagstaff, John" uniqKey="Wagstaff J" first="John" last="Wagstaff">John Wagstaff</name><affiliation><nlm:affiliation>The College of Medicine, Swansea University, Swansea, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Callahan, Margaret K" sort="Callahan, Margaret K" uniqKey="Callahan M" first="Margaret K" last="Callahan">Margaret K. Callahan</name><affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Postow, Michael A" sort="Postow, Michael A" uniqKey="Postow M" first="Michael A" last="Postow">Michael A. Postow</name><affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Smylie, Michael" sort="Smylie, Michael" uniqKey="Smylie M" first="Michael" last="Smylie">Michael Smylie</name><affiliation><nlm:affiliation>Cross Cancer Institute, Edmonton, Alberta, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Ferrucci, Pier Francesco" sort="Ferrucci, Pier Francesco" uniqKey="Ferrucci P" first="Pier Francesco" last="Ferrucci">Pier Francesco Ferrucci</name><affiliation><nlm:affiliation>Istituto Europeo di Oncologia, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Dummer, Reinhard" sort="Dummer, Reinhard" uniqKey="Dummer R" first="Reinhard" last="Dummer">Reinhard Dummer</name><affiliation><nlm:affiliation>University of Zurich, Zurich, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Hill, Andrew" sort="Hill, Andrew" uniqKey="Hill A" first="Andrew" last="Hill">Andrew Hill</name><affiliation><nlm:affiliation>Tasman Oncology Research, Brisbane, QLD, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Taylor, Fiona" sort="Taylor, Fiona" uniqKey="Taylor F" first="Fiona" last="Taylor">Fiona Taylor</name><affiliation><nlm:affiliation>Adelphi Values, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Sabater, Javier" sort="Sabater, Javier" uniqKey="Sabater J" first="Javier" last="Sabater">Javier Sabater</name><affiliation><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Walker, Dana" sort="Walker, Dana" uniqKey="Walker D" first="Dana" last="Walker">Dana Walker</name><affiliation><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kotapati, Srividya" sort="Kotapati, Srividya" uniqKey="Kotapati S" first="Srividya" last="Kotapati">Srividya Kotapati</name><affiliation><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Abernethy, Amy" sort="Abernethy, Amy" uniqKey="Abernethy A" first="Amy" last="Abernethy">Amy Abernethy</name><affiliation><nlm:affiliation>Duke University Medical Center, Durham, NC, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Long, Georgina V" sort="Long, Georgina V" uniqKey="Long G" first="Georgina V" last="Long">Georgina V. Long</name><affiliation><nlm:affiliation>Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia. Electronic address: georgina.long@sydney.edu.au.</nlm:affiliation></affiliation></author></analytic><series><title level="j">European journal of cancer (Oxford, England : 1990)</title><idno type="eISSN">1879-0852</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antibodies, Monoclonal (administration & dosage)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antineoplastic Agents (therapeutic use)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Double-Blind Method</term><term>Female</term><term>Health Status</term><term>Humans</term><term>Male</term><term>Melanoma (drug therapy)</term><term>Middle Aged</term><term>Quality of Life</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Health Status</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Quality of Life</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28651159</PMID><DateCreated><Year>2017</Year><Month>06</Month><Day>26</Day></DateCreated><DateCompleted><Year>2017</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0852</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><PubDate><Year>2017</Year><Month>Sep</Month></PubDate></JournalIssue><Title>European journal of cancer (Oxford, England : 1990)</Title><ISOAbbreviation>Eur. J. Cancer</ISOAbbreviation></Journal><ArticleTitle>Health-related quality of life results from the phase III CheckMate 067 study.</ArticleTitle><Pagination><MedlinePgn>80-91</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0959-8049(17)30995-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2017.05.031</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">HRQoL was assessed at weeks 1 and 5 per 6-week cycle for the first 6 months, once every 6 weeks thereafter, and at two follow-up visits using the European Organization for Research and Treatment of Care Core Quality of Life Questionnaire and the EuroQoL Five Dimensions Questionnaire. In addition to the randomised population, patient subgroups, including BRAF mutation status, partial or complete response, treatment-related AEs of grade 3/4, and those who discontinued due to any reason and due to an AE, were investigated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Nivolumab and ipilimumab combination and nivolumab alone both maintained HRQoL, and no clinically meaningful deterioration was observed over time compared with ipilimumab. In addition, similar results were observed across patient subgroups, and no clinically meaningful changes in HRQoL were observed during follow-up visits for patients who discontinued due to any cause.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results further support the clinical benefit of nivolumab monotherapy and nivolumab and ipilimumab combination therapy in patients with advanced melanoma. The finding that the difference in grade 3/4 AEs between the arms did not translate into clinically meaningful differences in the reported HRQoL may be relevant in the clinical setting.</AbstractText><AbstractText Label="STUDY NUMBER" NlmCategory="UNASSIGNED">NCT01844505.</AbstractText><CopyrightInformation>Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schadendorf</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larkin</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Royal Marsden Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolchok</LastName><ForeName>Jedd</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodi</LastName><ForeName>F Stephen</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiarion-Sileni</LastName><ForeName>Vanna</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Istituto Oncologico Veneto, Veneto, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Rene</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Colorado, Denver, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutkowski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grob</LastName><ForeName>Jean-Jacques</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Hospital de la Timone, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cowey</LastName><ForeName>C Lance</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Texas Oncology-Baylor Cancer Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lao</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagstaff</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The College of Medicine, Swansea University, Swansea, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callahan</LastName><ForeName>Margaret K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Postow</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smylie</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cross Cancer Institute, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrucci</LastName><ForeName>Pier Francesco</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Istituto Europeo di Oncologia, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dummer</LastName><ForeName>Reinhard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Tasman Oncology Research, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Fiona</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Adelphi Values, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabater</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Dana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotapati</LastName><ForeName>Srividya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abernethy</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Duke University Medical Center, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Georgina V</ForeName><Initials>GV</Initials><AffiliationInfo><Affiliation>Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia. Electronic address: georgina.long@sydney.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Cancer</MedlineTA><NlmUniqueID>9005373</NlmUniqueID><ISSNLinking>0959-8049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>31YO63LBSN</RegistryNumber><NameOfSubstance UI="C581771">nivolumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>6T8C155666</RegistryNumber><NameOfSubstance UI="C508317">ipilimumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Advanced melanoma</Keyword><Keyword MajorTopicYN="N">Checkpoint inhibitors</Keyword><Keyword MajorTopicYN="N">Health-related quality of life</Keyword><Keyword MajorTopicYN="N">Ipilimumab</Keyword><Keyword MajorTopicYN="N">Nivolumab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>05</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>05</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28651159</ArticleId><ArticleId IdType="pii">S0959-8049(17)30995-4</ArticleId><ArticleId IdType="doi">10.1016/j.ejca.2017.05.031</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000640 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000640 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28651159
|texte= Health-related quality of life results from the phase III CheckMate 067 study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28651159" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |